Healthcare
Live Price
Offline$60.28
+0.00% today
1Y Change
+4.46%
Window
Jun 26, 2025 โ Jun 17, 2026
Coverage: 245 bars ยท Jun 26, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Basilea Pharmaceutica AG (BPMUF) is a Healthcare stock with a market cap of $670.00M. The stock last traded around $60.27 and up 4.5% across the available one-year price window (Jun 26, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +11.5%, EPS growth of -48.8%, a dividend yield of 0.0%. What stands out right now is revenue +11.5%, EPS -48.8%, free cash flow -18.0% with operating margin 21.9% and ROIC 15.1%. Valuation is more restrained than many high-expectation growth names at P/E 20.6 and price/sales 3.7. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines BPMUF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.5% vs +7.6% peer median
Operating Margin
Above sector median
+21.9% vs +19.4% peer median
P/E
Below sector median
20.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 17, 2026 with an EPS surprise of -5.3% and a revenue surprise of +6.6%.
The operating picture looks softer than before
Revenue is at +11.5% and EPS is at -48.8%, with operating margin around 21.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 18, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.1% over the next 5 trading days and finished higher after 1 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 17, 2026 | -5.3% | +0.0% | +0.0% | +0.0% |
2025 Aug 19, 2025 | -43.8% | +0.0% | +0.0% | +0.0% |
2025 Feb 18, 2025 | +26.6% | +0.0% | +6.3% | +6.3% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BPMUF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BPMUF Max Drawdown
-18.55%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for BPMUF and SPY.
Company Overview
Basilea Pharmaceutica AG
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.